BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 7561922)

  • 1. Prognostic indicators in a range of astrocytic tumours: an immunohistochemical study with Ki-67 and p53 antibodies.
    Ellison DW; Steart PV; Bateman AC; Pickering RM; Palmer JD; Weller RO
    J Neurol Neurosurg Psychiatry; 1995 Oct; 59(4):413-9. PubMed ID: 7561922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor.
    Korkolopoulou P; Christodoulou P; Kouzelis K; Hadjiyannakis M; Priftis A; Stamoulis G; Seretis A; Thomas-Tsagli E
    Br J Cancer; 1997; 75(9):1269-78. PubMed ID: 9155045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apoptosis in cerebral astrocytic tumours and its relationship to expression of the bcl-2 and p53 proteins.
    Ellison DW; Steart PV; Gatter KC; Weller RO
    Neuropathol Appl Neurobiol; 1995 Aug; 21(4):352-61. PubMed ID: 7494604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gliomas of the optic nerve: histological, immunohistochemical (MIB-1 and p53), and MRI analysis.
    Cummings TJ; Provenzale JM; Hunter SB; Friedman AH; Klintworth GK; Bigner SH; McLendon RE
    Acta Neuropathol; 2000 May; 99(5):563-70. PubMed ID: 10805102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours.
    Jaros E; Perry RH; Adam L; Kelly PJ; Crawford PJ; Kalbag RM; Mendelow AD; Sengupta RP; Pearson AD
    Br J Cancer; 1992 Aug; 66(2):373-85. PubMed ID: 1503912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples.
    Sallinen PK; Haapasalo HK; Visakorpi T; Helén PT; Rantala IS; Isola JJ; Helin HJ
    J Pathol; 1994 Dec; 174(4):275-82. PubMed ID: 7884589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of the expression of tumor suppressor genes p53, p21, p16 and prb, and Ki-67 labelling in high grade astrocytomas treated with radiotherapy.
    Kirla R; Salminen E; Huhtala S; Nuutinen J; Talve L; Haapasalo H; Kalimo H
    J Neurooncol; 2000; 46(1):71-80. PubMed ID: 10896207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accumulation of p53 and Ki-67 expression do not predict survival in patients with fibrillary astrocytomas or the response of these tumors to radiotherapy.
    Hilton DA; Love S; Barber R; Ellison D; Sandeman DR
    Neurosurgery; 1998 Apr; 42(4):724-9. PubMed ID: 9574635
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic implication of the p53 protein and Ki-67 antigen immunohistochemistry in malignant fibrous histiocytoma.
    Yang P; Hirose T; Hasegawa T; Seki K; Sano T; Hizawa K
    Cancer; 1995 Aug; 76(4):618-25. PubMed ID: 8625155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of proliferation and apoptosis in brain gliomas: prognostic and clinical value.
    Heesters MA; Koudstaal J; Go KG; Molenaar WM
    J Neurooncol; 1999; 44(3):255-66. PubMed ID: 10720205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic relevance of TP53 mutations, p53 protein, Ki-67 index and conventional histological grading in oligodendrogliomas.
    Hagel C; Krog B; Laas R; Stavrou DK
    J Exp Clin Cancer Res; 1999 Sep; 18(3):305-9. PubMed ID: 10606174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 immunohistochemical positivity as a prognostic marker in intracranial tumours.
    Soini Y; Niemelä A; Kamel D; Herva R; Bloigu R; Pääkkö P; Vähäkangas K
    APMIS; 1994 Oct; 102(10):786-92. PubMed ID: 7826609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical analysis of bcl-2 and p53 expression in breast carcinomas: their correlation with Ki-67 growth fraction.
    Gorczyca W; Markiewski M; Kram A; Tuziak T; Domagala W
    Virchows Arch; 1995; 426(3):229-33. PubMed ID: 7773501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of the p53 protein in a spectrum of astrocytic tumours.
    Ellison DW; Gatter KC; Steart PV; Lane DP; Weller RO
    J Pathol; 1992 Dec; 168(4):383-6. PubMed ID: 1336544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Measurement of PCNA labeling index in astrocytic tumors].
    Beppu T; Arai H; Kanaya H; Sasaki K
    No Shinkei Geka; 1992 Dec; 20(12):1255-9. PubMed ID: 1362456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
    Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
    Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 protein overexpression in astrocytic neoplasms.
    Cho MY; Jung SH; Kim TS
    Yonsei Med J; 1995 Dec; 36(6):521-6. PubMed ID: 8599254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MIB-1 labeling index in astrocytic tumors--a clinicopathologic study.
    Neder L; Colli BO; Machado HR; Carlotti CG; Santos AC; Chimelli L
    Clin Neuropathol; 2004; 23(6):262-70. PubMed ID: 15584210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical analysis of cyclin A in astrocytic tumours.
    Chakrabarty A; Bridges LR
    Neuropathol Appl Neurobiol; 1998 Jun; 24(3):239-45. PubMed ID: 9717190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 expression and subcellular survivin localization improve the diagnosis and prognosis of patients with diffuse astrocytic tumors.
    Faccion RS; Bernardo PS; de Lopes GPF; Bastos LS; Teixeira CL; de Oliveira JA; Fernandes PV; Dubois LG; Chimelli L; Maia RC
    Cell Oncol (Dordr); 2018 Apr; 41(2):141-157. PubMed ID: 29374392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.